Thomas Jefferson University

Jefferson Digital Commons
Department of Medical Oncology Faculty
Papers

Department of Medical Oncology

1-1-2018

Determination of an optimal response cut-off able to predict
progression-free survival in patients with well-differentiated
advanced pancreatic neuroendocrine tumours treated with
sunitinib: an alternative to the current RECIST-defined response.
Angela Lamarca
Christie NHS Foundation Trust

Jorge Barriuso
Christie NHS Foundation Trust; University of Manchester
Follow
thisKulke
and additional works at: https://jdc.jefferson.edu/medoncfp
Matthew

Dana-Farber Cancer Institute
Part of the Oncology Commons

Ivan Borbath
Let
us know how access to this document benefits you
Cliniques Universitaires Saint-Luc

Recommended
Heinz-Josef
Lenz
Citation
University
of
Southern
California
Lamarca, Angela; Barriuso,
Jorge; Kulke, Matthew; Borbath, Ivan; Lenz, Heinz-Josef; Raoul, Jean
Luc; Meropol, Neal J.; Lombard-Bohas, Catherine; Posey, James; Faivre, Sandrine; Raymond, Eric;
and
Valle,
Juan
"Determination
See next
page
forW.,
additional
authors of an optimal response cut-off able to predict progressionfree survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours
treated with sunitinib: an alternative to the current RECIST-defined response." (2018).
Department of Medical Oncology Faculty Papers. Paper 75.
https://jdc.jefferson.edu/medoncfp/75
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Department of Medical Oncology Faculty Papers by an authorized administrator of the
Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Authors
Angela Lamarca, Jorge Barriuso, Matthew Kulke, Ivan Borbath, Heinz-Josef Lenz, Jean Luc Raoul, Neal J.
Meropol, Catherine Lombard-Bohas, James Posey, Sandrine Faivre, Eric Raymond, and Juan W. Valle

This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/medoncfp/75

FULL PAPER

British Journal of Cancer (2018) 118, 181–188 | doi: 10.1038/bjc.2017.402

Keywords: radiological response; RECIST; sunitinib; progression-free survival; neuroendocrine tumour; pancreas

Determination of an optimal response cut-off
able to predict progression-free survival in
patients with well-differentiated advanced
pancreatic neuroendocrine tumours treated
with sunitinib: an alternative to the current
RECIST-defined response
Angela Lamarca*,1, Jorge Barriuso1,2, Matthew Kulke3, Ivan Borbath4, Heinz-Josef Lenz5, Jean Luc Raoul6,
Neal J Meropol7,8, Catherine Lombard-Bohas9, James Posey10, Sandrine Faivre11, Eric Raymond12
and Juan W Valle*,1,13
Background: Sunitinib prolongs progression-free survival (PFS) in patients with advanced pancreatic neuroendocrine tumours
(pNET). Response Evaluation Criteria in Solid Tumors (RECIST)-defined partial responses (PR; classically defined as X30% size
decrease from baseline) are infrequent.
Methods: Individual data of pNET patients from the phase II [NCT00056693] and pivotal phase III [NCT00428597] trials of sunitinib
were analysed in this investigator-initiated, post hoc study. The primary objective was to determine the optimal RECIST (v.1.0)
response cut-off value to identify patients who were progression-free at 11 months (median PFS in phase III trial); and the most
informative time-point (highest area under the curve (AUC) by receiver operating characteristic (ROC) analysis and logistic
regression) for prediction of benefit (PFS) from sunitinib.
Results: Data for 237 patients (85 placebo; 152 sunitinib (n ¼ 66.50 mg ‘4-weeks on/2-weeks off’ schedule; n ¼ 86 ‘37.5 mg
continuous daily dosing (CDD)’)) and 788 scans were analysed. The median PFS for sunitinib and placebo were 9.3 months (95% CI
7.6–12.2) and 5.4 months (95% CI 3.5–6.01), respectively (hazard ratio (HR) 0.43 (95% CI 0.29–0.62); Po0.001). A PR was seen in 19
patients (13%) on sunitinib; the median change in the sum of the lesions (vs baseline) was  12.8% (range  100 to þ 36.4). Month
7 was the most informative time-point (AUC 0.78 (95% CI 0.66–0.9); odds ratio 1.05 (95% CI 1.01–1.08), P ¼ 0.002). Reduction of 10%
(vs baseline) achieved the highest sensitivity (50%) and specificity (82%), amongst cut-offs tested. A 10% reduction in marker
lesions was associated with improved PFS in the whole sunitinib population (HR 0.55 (95 CI 0.3–0.9); P ¼ 0.04); mostly in patients on
sunitinib CDD (HR 0.33 (95% CI 0.2–0.7); P ¼ 0.005). A 10% reduction in marker lesions (P ¼ 0.034) and sunitinib treatment (P ¼ 0.012)
independently impacted on PFS (multivariable analysis).
Conclusions: A 10% reduction within marker lesions identifies pNET patients benefiting from sunitinib treatment with implications
for maintenance of dose intensity and future trial design.
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Assessment of the change in tumour burden is an important
feature of the clinical evaluation of anticancer therapies. Response
Evaluation Criteria in Solid Tumours (RECIST) were reviewed in
2000 (Therasse et al, 2000) and 2009 (Eisenhauer et al, 2009) and
are widely employed in clinical trial and daily practice settings for
assessing response to treatment. With the development of new
targeted agents, the ability of RECIST to identify patients deriving
benefit from treatment has been questioned. The main reason is
because of the low rate of objective responses seen with targeted
agents, which does not seem to be a meaningful surrogate of
biological effect (where measures of improvement in progressionfree, morphological changes or overall survival are more appropriate) (Faivre et al, 2012).
Pancreatic neuroendocrine tumours (pNETs) are rare tumours,
for which targeted agents, such as sunitinib (Raymond et al, 2011)
or everolimus (Yao et al, 2011), have shown benefit by significantly
improving progression-free survival (PFS) in phase III trials
compared to placebo controls. Data supporting the use of sunitinib
in particular include a single-arm phase II study, using 50 mg per
day in the classical ‘4 weeks on/2 weeks off’ schedule (Kulke et al,
2008); and a randomised phase III study using 37.5 mg continuous
daily dosing (CDD) schedule (Raymond et al, 2011) achieving
response rates (by RECIST v1.0 (Therasse et al, 2000)) of 16.7%
and 9.3%, respectively. The pivotal phase III clinical trial
(Raymond et al, 2011), reported by Raymond et al in 2011,
randomised 171 patients diagnosed with advanced, progressive,
well-differentiated pNET to receive either CDD sunitinib (37.5 mg
daily) or placebo. The primary end-point of the study was median
PFS; this clinical trial identified significant longer PFS in patients
receiving sunitinib (11.4 versus 5.5 months; Hazard Ratio (HR)
0.42 (95% confidence interval (CI), 0.26–0.66; Po0.001); there
were eight objective partial responses (9.3%) with sunitinib (versus
none in the placebo group). Diarrhoea, nausea, vomiting, fatigue,
hand-foot skin reaction and hypertension were the most common
side effects.
Due to the low rate of partial response achieved with targeted
agents when the classical 30% tumour shrinkage cut-off is
employed (per RECIST v1.0 (Therasse et al, 2000) and v.1.1
(Eisenhauer et al, 2009)), and the questioned capacity of such
definition to identify patients benefiting from such treatment (in
terms of PFS), alternative cut-offs have been explored. As an
example, a modification of RECIST has been proposed for patients
with renal cell carcinoma (Thiam et al, 2010; Krajewski et al, 2011,
2014); Krajewski et al (2011, 2014) validated a different cut-off for
RECIST, able to identify more accurately those patients with
benefit (in terms of overall survival) from anti-angiogenic agents
(including sunitinib). Unfortunately, this has not been tested in
pNET as yet and therefore, partial response as per the current
definition (30% reduction) remains of limited value for patients’
management.
The aim of this analysis was to identify an alternative cut-off for
definition of partial response able to predict clinical benefit from
treatment with sunitinib in patients diagnosed with pNET.

MATERIALS AND METHODS

Study design. Patients diagnosed with well- and moderately
differentiated pNETs who received treatment with sunitinib/
placebo as part of the phase III (NCT00428597 (Raymond et al,
2011)) and phase II (NCT00428597 (Kulke et al, 2008)) clinical
trials were eligible for this investigator-initiated post hoc analysis.
Patients with other diagnoses, such as small bowel primary NET
(included in the phase II (NCT00428597 (Kulke et al, 2008))
clinical trial) were excluded. No other exclusion criteria were
applied. This study was approved by Pfizer, who facilitated access
182
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to anonymised individual-patient data (all patients had previously
provided informed consent to be involved in the above-mentioned
studies); all data employed in this study have previously been
collected by Pfizer and quality-assured for registration purposes.
Study was sponsored by The University of Manchester. Updated
outcome data (July 2014) including open-label extension phase was
included into this analysis.
Study population. All clinical data, including demographics,
treatment characteristics and radiological response assessment (as
per investigator assessment), together with progression-free and
overall survival collected within the above-mentioned studies were
retrieved. Best response was classified as complete response, partial
response, stable disease or progressive disease based on previously
reported assessment by investigators involved in the phase II and
phase III studies (RECIST v1.0 was employed) (Therasse et al,
2000). Changes within sum of tumour diameter compared to
baseline/nadir in each one of the radiological assessment perfumed
for each individual patient was calculated following RECIST v1.0
for this post hoc analysis (Therasse et al, 2000); should the
measurement of one of the marker lesion be unavailable for a
specific radiological assessment, such radiological assessment was
considered not-evaluable.
Study objectives. The primary objective of this post hoc analysis
was to determine an alternative cut-off to the currently employed
reduction of 30% of sum of marker lesions diameter in order to
define partial response. We aimed to find the most informative
RECIST response cut-off value (identified as the percentage cut-off
value with maximum sensitivity and specificity in the ROC analysis
evaluating patients as progression-free at 11 months); this timepoint was pre-defined as the median PFS observed in the pivotal
phase III study was 11.4 months.
Secondary objectives included (a) identification of the most
informative assessment time-point (identified by the highest AUC)
for prediction of clinical benefit from sunitinib (defined as
progression-free at 11 months), (b) analysis of the impact of the
new RECIST cut-off in prediction of PFS in patients treated with
sunitinib/placebo, and (c) identification of the time-point with
higher rate of best-response.
Statistical analysis. No formal sample size calculation was
performed. All eligible patients were included in the analysis.
Due to limited sample size, it was not feasible to divide the
sunitinib-treated patients into training and validation cohorts;
therefore, all sunitinib-treated patients were analysed together.
Receiver operating characteristic (ROC) analysis was used to
identify the most informative scan time-point (month 1, month 2,
month 3, month 5, month 7, month 9 and month 11 and all
radiological assessment performed thereafter) by plotting RECIST
evaluation against PFS dichotomised by progression-free status at
11 months (yes vs no). This was facilitated by the fact that both
trials (NCT00056693 and NCT00428597) had the radiological
reassessment performed at these same time-points. The most
suitable time-point was selected by comparing the area under the
curve (AUC) from the ROC curves for each time-point and by
performing logistic regression analysis. Those time-points with
highest AUC (AUC of X0.7 were pre-defined as being ‘of interest’)
which also achieved statistically significant prediction by logistic
regression (two sided P-valueo0.05) were compared by ROC
curve comparison analysis for selection of the most informative
radiological assessment time-point. From this selected time-point,
the performance of 30% reduction and other alternative cut-offs
(20, 15 and 10%) were tested for prediction of progression-free at
11 months: guided by the highest sensitivity and specificity an
alternative cut-off for new definition of partial response was
identified. This alternative cut-off was employed to the achieved
best-response for survival analysis.
www.bjcancer.com | DOI:10.1038/bjc.2017.402
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Log-rank test, Kaplan-Meier method and Cox-regression
(univariate) were used to assess the impact of both the standard
30% cut-off and our newly-defined cut-off on PFS. PFS was defined
as the time from first-sunitinib dose (applicable for patients
included in the phase II) or randomisation (applicable for patients
included in the phase III) to the first evidence of progression or
death from any cause. Survival analysis was replicated in patients
treated with placebo with the intention of clarifying whether
radiological response was a prognostic or a predictive factor. A
multivariable analysis (Cox regression) adjusted for other known
prognostic factors was performed.
RESULTS

A total of 237 patients and 788 scans were included in this post hoc
analysis. Data for a total of 152 sunitinib-treated patients (66 from
the phase II study and 86 from the phase III study) and 85 patients
treated with placebo was received (Supplementary Figure 1).
Patient characteristics, response to treatment and outcomes.
The median age of the whole population was 56 years (range
25–84years), most patients were of Eastern Cooperative Oncology
Group performance status (ECOG-PS) 0 (54%) or 1 (45%). The
dose of sunitinib/placebo was 37.5 mg daily for all patients
included in the phase III study; patients included into the phase
II received 50 mg daily of sunitinib on a ‘4 weeks on, 2 weeks off’
schedule. Table 1 summarises baseline characteristics of the
patients included in our analysis.
Patient outcomes are summarised in Table 1. The median
follow-up was 16.5 months for the whole population (12, 32.5 and
23.2 months for patients treated with sunitinib in the phase II,
phase III and placebo arm patients, respectively; Supplementary
Table 1). Patients treated with sunitinib (all patients) and placebo
achieved a median PFS of 9.3 months (95% CI 7.6–12.2) and 5.4
months (95% CI 3.5–6.01), respectively; hazard ratio (HR) 0.43
(95% CI 0.29–0.62), P-value o0.001 (Figure 1A). Median PFS was
9.3 (95% CI 7.1–11.9) and 12.6 (95% CI 7.4–16.8) for sunitinibtreated patients in the phase II and phase III, respectively
(Supplementary Table 1).
Out of the whole population, 8% of patients were classified by
the local investigator to have achieved a partial response: 13% of
patients treated with sunitinib and 0% of patients in the placebo
treatment. As per calculations performed in this post hoc analysis,
the median time to best-response was 3 months in the
sunitinib arm and 83.7% of patients achieved the best response
by month 7 of treatment (Table 1 and Supplementary Table 2).
Median best change in the sum of marker lesions as per
calculations performed in this post hoc analysis was  12.8% and
þ 1.7% for patients with sunitinib and placebo, respectively
(Table 1, Figure 1B and C).
Identification of the most informative time-point. Radiological
assessment performed at month 5, month 7 and at the time of
‘best-response’ were the three time-points achieving both an AUC
higher than 0.7 and statistically significant prediction of being
progression-free at 11 months (logistic regression) (Table 2).
Therefore, these three time-points were compared by ROC curve
evaluation: although differences between the three time-points
were not statistically significant (P-value 0.3733 (Supplementary
Figure 2), month 7 maintained the highest AUC (0.75 (95% CI
0.63–0.86) and was therefore selected as the most informative
time-point. The observed median time on treatment in the
sunitinib group was 6.4 months (Table 1) supported this approach.
Alternative cut-off for new definition of ‘partial response’.
Fifty-four scans were available at month 7 and were used for the
identification of the alternative response cut-off. Performance of
www.bjcancer.com | DOI:10.1038/bjc.2017.402
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30% reduction in sum of marker lesions and other alternative
cut-offs (20, 15 and 10%) were tested for prediction of being
progression-free at 11 months (Table 3). A RECIST reduction of
10% was the most informative cut-off with highest rate of correctly
classified patients (66.7%), maintaining an admissible specificity
(82%). Since month 5 achieved a similar AUC to month 7 at the
identification of the most informative time-point (Table 2 and
Supplementary Material 4), alternative cut-offs were tested in this
time-point, to confirm the consistency of our alternative cut-off
(Supplementary Material 4). In addition, when this 10% cut-off
was applied to the best-response scans, it significantly increased the
number of patients classified as ‘partial response’ (59%), compared
to the more restrictive 30% cut-off, which classified ‘partial
responses’ in 20% of patients.
Survival analysis. Survival analysis was employed to compare the
impact on PFS of achieving a partial response according to the
classical 30% cut-off or our proposed alternative (10% reduction).
Univariate analysis confirmed that the 10% reduction in sum of
marker lesions cut-off impacted PFS for sunitinib-treated patients
(HR 0.55 (95% CI 0.31–0.97); P-value 0.04), while the 30% cut-off
did not (P-value 0.198) (Table 4). The benefit was even more
marked when the analysis was limited to the phase III sunitinibtreated patients (37.5 mg CDD) were analysed (HR 0.33 (95% CI
0.15–0.72); P-value 0.005; median PFS for patients achieving 10%
reduction was 13.60 months (95% CI 7.39-not reached) and it was
6.01 months 95% CI 2.10–not reached) for those who did not
(Figure 2)). Similar results were achieved in the placebo-treated
patients. Results were not reproduced in the phase II study (Pvalue 0.980). See Table 4 for full details.
Multivariable analysis confirmed that both treatment with
sunitinib and achieving a 10% of reduction in tumour diameter
were independent prognostic factors for longer PFS (Table 4);
achieving a response of 30% was not an independent prognostic
factor in the multivariable analysis (see Supplementary Table 3) for
full detail regarding univariate and multivariable analysis).
DISCUSSION

There is a need for optimising our currently-available tools for
radiological assessment of response in patients with NETs.
This could be done by (1) maximising the information provided by current standard size-based criteria (such as RECIST),
(2) incorporation of morphological assessment (e.g., Choi criteria
(Faivre et al, 2012)) or by (3) incorporating metabolic techniques
(nuclear medicine (Sundin and Rockall, 2012)) into response
assessment. This study focused on the first approach.
This post hoc analysis is the first study to identify an alternative
tumour shrinkage cut-off for definition of partial response in
sunitinib-treated pNET patients. While the classical cut-off of 30%
of tumour diameter reduction was shown to be too restrictive and
not impacting PFS in the multivariable analysis, our proposed
alternative of 10% reduction did impact PFS, even when adjusted
to other prognostic factors.
Best-response to treatment was achieved early-on in the
treatment with sunitinib: at a median of 3 months to bestresponse, with 83.9% of patients achieving the best-response
during the first 7 months of treatment. Therefore, this alternative
definition of objective partial response can be used as an early
marker of benefit from treatment and could impact patients’
management.
Our results support that a reduction of 10% may be used as an
accurate surrogate for PFS. Earlier studies have shown the
importance of maintenance of dose intensity in sunitinib-treated
patients in renal cell carcinoma (RCC) (Houk et al, 2010). We
would therefore suggest that dose reduction rather than dose
183
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Table 1. Baseline characteristics of the patients included in our analysis
All patients (n ¼ 237)

Sunitinib group (n ¼ 152)

Control group (Placebo;
n ¼ 85)

Age at study entry (years)
Median (range)
X 65 years old

56 (25–84)
55 (23%)

56 (25–84)
32 (21%)

57 (26–78)
23 (27%)

Gender
Male (n (%))
Female (n (%))

124 (52%)
113 (48%)

84 (55%)
68 (45%)

40 (47%)
45 (53%)

Race
White (n (%))
Black (n (%))
Asian (n (%))
Other (n (%))

160 (67%)
4 (2%)
24 (10%)
49 (21%)

107 (70%)
4 (3%)
14 (9%)
27 (18%)

53
0
10
22

ECOG PS at study entry
0 (n (%))
1 (n (%))
2 (n (%))

129 (54%)
107 (45%)
1 (1%)

88 (59%)
64 (42%)
0 (0%)

41 (48%)
43 (51%)
1 (1%)

Functioning tumour
Yes (n (%))
No (n (%))
Unknown (n (%))

104 (44%)
132 (55%)
1 (1%)

63 (41%)
88 (58%)
1 (1%)

41 (52%)
44 (48%)
0 (0%)

First diagnosis Z3 years before inclusion in trial
Yes (n (%))
No (n (%))
Unknown (n (%))

103 (43%)
133 (56%)
1 (1%)

55 (36%)
96 (63%)
1 (1%)

48 (56%)
37 (44%)
0 (0%)

Previous systemic treatment (excluding SSA)
Yes (n (%))
No (n (%))

135 (57%)
102 (43%)

85 (56%)
67 (44%)

50 (59%)
35 (41%)

Is sunitinib/placebo 3rd line of treatment or more
(excluding SSA)?
Yes (n (%))
No (n (%))

70 (30%)
167 (70%)

45 (30%)
107 (70%)

25 (29%)
60 (71%)

Dose of sunitinib/placebo
37.5 mg od

171 (72%)

86 (57%)

85 (100%)

66 (28%)

66 (43%)

0 (0%)

16.5 (0.1–80.6)
7.7 (95%-CI 7.1–9.3)
112 (47%)
32 (14%)
5.1 (0–20.1)

15.6 (0.1–80.3)
9.3 (95% CI 7.6–12.2)
63 (41%)
27 (18%)
6.4 (0.4–19.7)

23.2 (0.1–80.6)
5.4 (3.5–6.01)
49 (58%)
5 (6%)
3.7 (0–20.1)

19 (8%)
150 (63%)
35 (15%)
33 (14%)
-5.7 (-100–43.3%)

19 (13%)
101 (66%)
14 (9%)
18 (12%)
-12.8 (-100–36.4)

0 (0%)
49 (58%)
21 (25%)
15 (17%)
1.7 (-46.7–43.3)

1 (1–17)
788

3 (1–17)
535

1 (1–13)
253

Patient demographics

50 mg od (4 þ 2)

(62%)
(0%)
(12%)
(26%)

Patient outcomes
Follow-up, median (range)
PFS (estimated median KM)a, median (95% CI)
Events PFS, yes (n (%))
Free-of progression at 11 months, yes (n (%))
Median time on treatment (months), median (range)
Best radiological response (defined by local
investigator)a
Partial response (n (%))
Stable disease (n (%))
Progressive disease (n (%))
Indeterminate (n (%))
Best change in sum of marker lesions (%)b, median
(range)
Time of scan with best-responseb, median (range)
Number of scans availableb, total number

Abbreviations: ECOG-PS ¼ Eastern Cooperative Oncology Group performance status; KM ¼ Kaplan–Meier estimation; n ¼ number of patients; PFS ¼ progression-free survival; SSA ¼
somatostatin analogue.
a
As defined by local investigator.
b
As per calculations performed in this post hoc analysis.

interruption is considered in the event of treatment-related toxicity
for those patients who have achieved our suggested 10% reduction
on the size of targeted lesions, in accordance with the prescribing
information. Moreover, since, as mentioned above, the bestresponse was achieved early-on following initiation of treatment,
we also argue that should patients not achieve a 10% of tumour
shrinkage after 7 months of treatment, the dose of sunitinib could
be increased to 50 mg daily (if well tolerated) as suggested in the
sunitinib SPC (EMA, 2016) and as detailed in the phase III clinical
trial protocol which stated that ‘in patients without an objective
184

tumour response who had grade 1 or lower non-haematologic or
grade 2 or lower haematologic treatment-related adverse events
during the first 8 weeks, the dose could be increased to 50 mg per
day’ (Raymond et al, 2011). Although dose escalation of sunitinib
has been explored in RCC and gastrointestinal stromal tumour
(GIST) (Patel, 2012; Ornstein et al, 2016; Shi et al, 2016),
experience of doing so in pNET is limited; only 10% of patients
treated with sunitinib in the phase III pivotal clinical trial had dose
increased to 50 mg daily, and its impact is unclear (Raymond et al,
2011).
www.bjcancer.com | DOI:10.1038/bjc.2017.402
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A

B

Progression-free survival (all patients)

C

Sunitinib-treated patients (n=152)

Placebo-treated patients (n=85)
50

50

1.00

HR 0.43 (95% Cl 0.29–0.62)
P-value <0.001

0.50
0.25
0.00
0

5

10

15

20

Progression-free survival (months)
Number at risk
Sunitinib 152
Placebo 85

Change from baseline (%)

Sunitinib
Placebo

0.75

Change from baseline (%)

Probability of survival (%)
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0

–50

–100
80
26

29
5

6
2

0

–50

–100

0
1

Confirmed progression

Confirmed progression

Figure 1. Outcome of patients treated with sunitib/placebo. Progression-free survival in patients with sunitinib and placebo (A); Waterfall-plot
showing best changes in sum of marker lesions in patients treated with sunitinib (B) and placebo (C). HR, hazard ratio; 95% CI, 95% confidence
interval; n, number of patients.

Table 2. Identification of the most informative time-point employing ROC curve analysis (AUC) and logistic regression for
prediction of progression-free at 11 months
ROC analysis

Logistic regression

ROC curve comparison analysis

Time-point

Number of
observations

AUC (95% CI)

Logistic Regression
OR (95% CI)

Logistic Regression
P-value

AUC (95% CI)

Number of
observation

Best response

144

0.77 (0.67–0.86)

1.05 (1.02–1.07)

o0.001

0.66 (0.53–0.79)a

68

Month 1

134

0.67 (0.54–0.78)

1.05 (1.01–1.1)

0.011

Not included

—

Month 2

68

0.57 (0.43–0.72)

1.01 (0.98–1.04)

0.489

Not included

—

Month 3

107

0.60 (0.48–0.74)

1.02 (1.01–1.04)

0.037

Not included

—

Month 5

79

0.76 (0.65–0.86)

1.04 (1.02–1.06)

0.001

0.74 (0.62–0.86)a

68

Month 7

54

0.78 (0.66–0.9)

1.05 (1.01–1.08)

0.002

0.75 (0.63–0.86)a

68

Month 9

38

0.73 (0.54–0.91)

1.04 (0.99–1.1)

0.078

Not included

—

Month 11

24

0.64 (0.26–1)

1.02 (0.98–1.06)

0.370

Not included

—

Month 13

18

0.49 (0.1–0.96)

0.99 (0.97–1.02)

0.553

Not included

—

Month 15

8

0.60 (0–1)

0.98 (0.94–1.03)

0.496

Not included

—

Month 17

2

—

—

—

Not included

—

Month 19

2

—

—

—

Not included

—

Month 21

1

—

—

—

Not included



Abbreviations: AUC ¼ area under the curve; CI ¼ confidence interval; OR ¼ odds ratio; ROC ¼ receiver operating characteristic.
a
Chi-square P-value 0.3733 (Supplementary Figure 3).

Table 3. Identification of alternative cut-offs for definition of
‘partial response’ employing data from the 54 scans available
at month 7

Cutoff

Number of patients
classified as
response when this
Correctly cut-off is employed
classified to the best-response
assessmenta
Sensitivity Specificity patients (%)

 30%

31%

96%

64.8%

29 (20%)

 20%

39%

89%

64.8%

51 (35%)

 15%

46%

86%

66.7%

61 (42%)

 10%

50%

82%

66.7%

84 (59%)

a

As per calculations performed in this post hoc analysis.

Alternative response cut-offs have also been explored in the past in
other malignancies such as RCC, in which targeted therapies
(including sunitinib) are a cornerstone of systemic management
(Thiam et al, 2010, Krajewski et al, 2011, 2014). Krajewski et al (2011,
www.bjcancer.com | DOI:10.1038/bjc.2017.402

2014) validated a different cut-off for RECIST criteria, able to identify
more accurately those patients with benefit (in terms of overall
survival) from anti-angiogenic agents (including sunitinib). In keeping
with our findings, a cut-off of 10% of the sum of the longest tumour
diameter shrinkage on the first follow-up CT scan was predictive of
outcome, however, some challenges existed such as the lack of placebotreated patients which did not allow them to explore whether the new
cut-off was a predictive factor or not (Chen et al, 2014). The fact that
similar findings have been shown in small series of gastrointestinal
NETs treated with somatostatin analogues provide robustness to our
findings (Luo, 2017). In this series, Luo et al included 33 patients with
NETs treated with SSA; the authors identified that achieving a
response of 10% reduction in target lesions impacted PFS.
Our study has some note-worthy strengths such as the fact that
all data were prospectively collected as part of phase II and phase
III clinical trials, in addition to the previous quality-assurance of
these data for registration purposes. We also explored first which
was the most informative time-point, in order to calculate the
response cut-off at such time-point; this, was one of the
acknowledged limitations of the previous studies in RCC (Chen
et al, 2014). Although the use of morphological changes (such as
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Table 4. Survival analyses: median PFS estimations (Kaplan–Meier method) and univariate and multivariable Cox regression
analyses
Univariate analysis (by type of treatment and response)

Variable

Group

Median PFS in the
responding group
(months) (KM)

All patients treated
with Sunitinib
(n ¼ 144)

Best-response
cut-off

 30%

12.23 (8.32–14.99)

 10%

10.98 (8.28–12.71)

0.55 (0.31–0.97)

0.040

Phase III patients
treated with
Sunitinib (n ¼ 80)

Best-response
cut-off

 30%

13.60 (7.49-nr)

10.15 (7.19-nr)

0.68 (0.28–1.62)

0.386

 10%

13.60 (7.39-nr)

6.01 (2.10-nr)

0.33 (0.15–0.72)

0.005

Phase II patients
treated with
Sunitinib (n ¼ 64)

Best-response
cut-off

 30%

10.98 (7.79–14.99)

7.63 (6.61–12.26)

0.48 (0.21–1.13)

0.093

 10%

9.30 (7.10–12.23)

7.63 (6.54-nr)

1.01 (0.42–2.43)

Placebo-treated
patients

Variable

Group

Median PFS in the
responding group
(months)

Best response
cut-off

 30%

Nr (nr-nr)

Sunitinib-treated
patients

Phase III patients
treated with Placebo
(n ¼ 76)

 10%

Median PFS in the nonresponding group (months)

Univariate COX (HR 95%

CI)

Univariate
COX P-value

8.28 (7.10–12.49)

0.69 (0.38–1.22)

0.198

7.63 (6.54–12.92)

0.980

Median PFS in the nonUnivariate COX (HR 95%-CI)
responding group (months)

9.63 (9.63-nr)

Univariate
COX Pvalue

5.42 (3.38–6.01)

0.59 (0.08–4.43)

0.616

3.84 (3.38–5.65)

0.30 (0.09–0.99)

0.050

Univariate/multivariable anlaysis (by type of treatment and response)
Group

Median PFS
(months) KM

Placebo
Sunitinib

5.42 (3.48–6.01)
9.30 (7.63–12.26)

No

7.39 (6.01–8.27)

Yes

11.97 (9.27–14.99)

No

5.85 (3.98–7.39)

Yes

10.99 (8.32–12.2)

Variable

Treatment
Classical cut-off
(30%)
Alternative Cut-off
(10%)

Univariate COX-regression

Multivariable COX-Regression (n ¼ 220)

HR (95% CI)

P-value

HR (95%-CI)

P-value

1 (Ref.)
0.43 (0.29–0.62)


o0.001

1 (Ref.)
0.56 (0.36–0.89)


0.014

1 (Ref.)

1 (Ref.)



0.56 (0.34–0.93)

0.026

1 (Ref.)

0.95 (0.52–1.75)

0.877

1 (Ref.)


o0.001

0.42 (0.28–0.62)





0.57 (0.34–0.97)

0.038

Abbreviations: CI ¼ confidence interval; ECOG PS ¼ Eastern Cooperative Oncology Group Performance Status; HR ¼ hazard ratio; KM ¼ Kaplan–Meier estimation; n ¼ number of patients;
NR ¼ not reached; PFS ¼ progression-free survival; Ref. ¼ reference category.

10% Cutoff

10.15 (7.19-nr) vs. 13.60 (7.49-nr)
HR 0.68 (95% Cl 0.28–1.62)
P-value 0.386

0.75
0.50
0.25
0.00
0

5

10

15

20

Probability of survival (%)

Probability of survival (%)

30% Cutoff

1.00

1.00

6.01 (2.10-nr) vs. 13.60 (7.39–nr)
HR 0.33 (95% Cl 0.15–0.72)
P - value 0.005

0.75
0.50
0.25
0.00
0

Progression-free survival (months)
Number at risk
No response 64
Response 16

27
11
No response

11
7

2
2

5

10

15

20

Progression-free survival (months)
0
0

Response

Number at risk
No response 31
Response 49

9
29

2
16

No response

0
4

0
0

Response

Figure 2. Progression free-survival in patients treated with 37.5 mg continuously of sunitinib (Phase III clinical trial), both cut-offs (classical 30%
and our proposed alternative 10%) are tested. CI=confidence interval; HR ¼ hazard ratio; 95% nr ¼ not-reached.

Choi criteria (van der Veldt et al, 2010)) have been suggested in
order to improve assessment of response to targeted therapies, the
incorporation of such approaches to daily practice could be
challenging due to the fact that it requires specialist radiological
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input for assessment of changes within density of target lesions
(Faivre et al, 2012). We do therefore believe that the application of
our 10% alternative cut-off could be relatively straight-forward for
clinicians managing patients with pNETs in daily practice.
www.bjcancer.com | DOI:10.1038/bjc.2017.402
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Limitations of our study include the fact that our analysis was
limited to the measurement of marker lesions; appearance of new
lesions could not be included in our analysis since it is not included
in the calculation of change in percentages of response. Whether
this radiological response is a predictive factor in addition to
prognostic remains unclear, since patients treated with placebo
who achieved such response did benefit in terms of PFS as well. It
is worth highlighting the fact that the phase III study included in
this analysis was interrupted early by the independent data
monitoring committee (IDMC); and that following final results
and demonstration of superiority of sunitinib, cross-over was
allowed. Thus, the fact that some of the patients initially allocated
to the placebo arm will have been treated with sunitinib (including
patients in the absence of disease progression) could also explain
why some patients in the placebo arm did have radiological
response to treatment and its impact on prognosis regardless of the
treatment group (as shown in the multivariable analysis). This
would warrant further investigations in future placebo-controlled
clinical trials. Another of the limitations from our study was that
different sunitinib schedules were used across the phase II and the
phase III studies. We do wonder whether this could be the
explanation why we were unable to replicate the differences in
median PFS found in the phase III study when comparing patients
who did/did not reach the 10% alternative cut-off in the phase II
patient population. The higher partial response rate identified in
the phase II study patients could have also contributed to this.
Finally, since the limited sample size did not allow us to divide our
sample in separate design and validation cohorts, our results
should be validated in future prospective series or clinical trials.
Finally, it could also be argued that the 10% reduction in sum of
marker lesions might be included within the expected interobserver and inter-examination variability, especially when CT
scans are performed as part of the daily practice and
assessed outside the setting of a prospective clinical trial.
It is worth highlighting that, although we do agreed with
this being a possibility we do believe it is unlikely to happen due
the fact that the CT scans employed in this study were not
centrally reviewed and that the assessments and measurements
were based on local radiologist (therefore reflecting standard
clinical practice).
In conclusion, our results support that reduction of 10% in the
measurement of marker lesions, impacts on PFS and should be
considered enough to classify pNET patients as responders to
sunitinib and likely to derive clinical benefit from treatment.
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